In patients with non-ST-elevation ACS and T2DM, Jeong et al. [23] described an improvement of brachial FMD, increased counts of circulating endothelial progenitor cells and decreases in interleukin-6 and tumor necrosis factor-α levels in patients with T2DM randomized to ticagrelor vs. prasugrel for 5 weeks, despite similar platelet reactivity on ticagrelor and prasugrel. Here, IL6 is linked to type 2 diabetes mellitus.